Samsung Biologics Plans 3 Trillion Won Rights Offering for Expansion
Samsung Biologics will raise approximately 3 trillion won through a rights offering to fund its next-phase growth and support the PolyPeptide acquisition. The capital raise aims to strengthen the biopharmaceutical company’s manufacturing and research capabilities.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (43/100)Sources
Samsung Biologics to Raise $2.2 Billion to Fund PolyPeptide Deal
Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.
By Youkyung Lee and Denny Thomas
Read full article →Samsung Biologics to raise 3 tr won via rights offering
Samsung Biologics announced Friday it would raise 3 trillion won ($2.17 billion) through a rights offering as part of efforts to fund investments in its long-term growth strategy. Some 2.71 trillion won from the offering proceeds will be used for its planned acquisition of the Swiss-based PolyPeptide Group, the biotech arm of Samsung Group said. In July, the company had announced plans to acquire the specialized contract development and manufacturing firm as part of efforts to expand its portfol
By The Korea Herald
Read full article →Samsung Biologics to raise 3 tln won via rights offering
SEOUL, Aug. 28 (Yonhap) -- Samsung Biologics announced Friday it would raise 3 t...
By Kang Jae-eun
Read full article →Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion - Taiwan News
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion Taiwan News
Read full article →
